Well, as I understand it, the concern was that the generic medicine was interchanged with the brand-name medicine without the patient’s being notified.
We talked earlier about the multiple jurisdictions in Canada. The issue of whether a patient should be notified when products are switched is a matter for the provincial college of pharmacy. Certainly, as generic drug manufacturers, we are quite confident and supportive of full information going to the patient. We would be very supportive of a national policy requiring that the patient be notified of any switch from a brand to a generic. That's certainly the situation in a number of provinces, including in Ontario. That's the first point.
The second point is, in terms of adverse drug reactions, they happen. There are no more reactions from either brand-name or generic medicines. In this case, if there has been, we feel bad about that. There is an opportunity for doctors to put on medication “No Substitution”. Most drug plans will accept those if it's a medically necessary reason, a valid reason.
Those are my comments on that.